ICH M11 CeSHarP in Canada: Preparing Clinical Trial Protocols for Structured Templates

In early November 2026, Health Canada published a notice confirming it has begun the phased implementation of ICH M11, the Clinical electronic Structured Harmonised Protocol, known as CeSHarP. For Canadian clinical trial sponsors, this is the start of a shift in how protocols are written and, eventually, how they are exchanged as structured data. Phase 1 is open now, which means you can already submit protocols that follow the ICH M11 structure and content in familiar document formats. This article explains what M11 is, what Health Canada has actually said, and how to prepare your protocol templates and processes before structured submission becomes the norm.

Executive summary

Clinical trial protocols have never had a single, common structure. Every sponsor, and often every therapeutic area, has used its own template, which slows regulatory review and makes global development harder to coordinate. ICH M11 addresses that by harmonising the structure and content of the protocol itself. The ICH Assembly adopted M11 for implementation on 19 November 2025, and ICH members, including Health Canada, are now rolling it out.

Health Canada's notice sets out a sensible, staged approach. Phase 1 is document based: sponsors prepare protocols that follow the M11 guideline and template, and submit them in PDF or DOCX using existing processes. Phase 2 will introduce structured electronic submission in formats such as JSON or XML, once Health Canada has published the technical specifications, guidance and timelines. The notice does not set a hard deadline for mandatory use, and it frames Phase 1 as something sponsors can begin now. The smart position is to treat M11 as the new default template, align your document and quality systems to it, and watch for Health Canada's Phase 2 announcements. This article walks through the three M11 deliverables, the phased rollout, the scope, and a practical readiness checklist.

What is ICH M11 CeSHarP?

What it is: ICH M11 is a multidisciplinary ICH guideline that harmonises the structure and standardised content of clinical trial protocols. Why it matters: a common protocol format makes regulatory review faster, reduces rework across regions, and prepares the ground for protocols exchanged as structured data rather than static documents. What to do: adopt the M11 template as your standard and understand its three parts.

CeSHarP, the Clinical electronic Structured Harmonised Protocol, is delivered as three connected parts:

Deliverable	What it provides
The Guideline	The general protocol design principles and the approach used to build the template and technical specification.
The Protocol Template	The format and structure of the protocol, including a standardised table of contents, universal headings and text, and instructions for where content belongs.
The Technical Specification	The data elements and technical attributes, such as definitions, conformance requirements and cardinality, that allow protocol content to be exchanged electronically.

In plain terms, the Guideline explains the thinking, the Template gives you the document to fill in, and the Technical Specification is the machine-readable layer that makes structured submission possible later. A sponsor adopting M11 today mainly works with the Guideline and the Template. The Technical Specification matters most when Health Canada moves to Phase 2.

Why ICH M11 matters for Canadian sponsors

What it means: Health Canada is a standing regulatory member of ICH and is committed to adopting ICH guidance, so M11 is coming to Canadian submissions. Why it matters: sponsors who run trials in several regions can use one protocol structure across them, and reviewers see a predictable layout. What to do: align your Canadian protocol templates with M11 so you are not maintaining a separate Canadian format.

Harmonisation is the theme across Health Canada's current clinical agenda. The move to M11 sits alongside the interim clinical trial policy, the Access Consortium work-sharing pilots and tighter expectations for paediatric dossiers under the 180-day paediatric review. A sponsor that standardises on M11 now reduces friction across all of these, because the same structured protocol feeds multiple review pathways. If you also run trials under the FDA, the expedited IND pilot and the US adoption of M11 point the same way, toward a single, structured protocol that travels.

Health Canada's phased implementation, step by step

What it is: a two-phase rollout that moves from document-based protocols to structured electronic submission. Why it matters: it tells you what to do now and what to prepare for. What to do: start Phase 1 adoption immediately and build the capability for Phase 2.

Phase	What it involves	Timing	Formats
Phase 1: Document based	Submit protocols that follow the ICH M11 structure and content, using existing preparation and submission processes.	In effect now, upon publication of the notice.	PDF or DOCX (Word)
Phase 2: Structured data	Submit protocols in structured electronic formats, consistent with the long-term M11 vision.	No date yet; introduced after Health Canada publishes technical specifications, guidance and timelines.	Structured formats such as JSON or XML

Health Canada says sponsors may now begin submitting clinical trial protocols using the ICH M11 harmonised structure and content in PDF or Word. It also says it will engage sponsors, industry associations, technology vendors and contract research organisations as it works toward Phase 2, and will communicate implementation timelines and technical considerations as they become available. For planning, treat Phase 1 as live and Phase 2 as a known but undated future state. Our Q4 2026 regulatory deadline calendar is a useful place to track Health Canada announcements as they land.

Is the M11 template mandatory in Canada yet?

What to know: Health Canada's notice does not use the words mandatory or voluntary, and it does not set a compliance date. It states that sponsors must submit protocols that align with the ICH M11 guideline in Phase 1, while also saying sponsors may now begin using the format. Because the notice reads as an option that is open now rather than a dated requirement, the honest answer is that there is no published mandatory date. What to do: adopt M11 as your default, and confirm the current expectation with Health Canada for any specific, active submission before you rely on a particular interpretation.

What the harmonised protocol template changes in practice

What changes: the protocol gains a standardised table of contents, universal headings and set instructions for where content belongs. Why it matters: content that used to move around now has a fixed home, which affects your template, your writing process and your quality review. What to do: map your current protocol sections to the M11 template and rebuild your authoring template around it.

A standardised structure sounds administrative, but it has real downstream effects. Medical writers stop debating section order and focus on content. Reviewers, internal and regulatory, find information in the same place every time, which speeds quality review and approval. When Phase 2 arrives, a protocol already written to the M11 template is far easier to convert to structured data, because the data elements line up with the headings you are already using. Sponsors who wait until structured submission is mandatory will face two changes at once, the template and the technology. Sponsors who adopt the template now face only one change later.

There is a practical migration cost. Your protocol template, authoring guidance, and any protocol-derived documents, such as the statistical analysis plan outline or the informed consent framework, should be checked against the M11 structure. Quality and regulatory teams need to learn the new layout so review comments do not fight the template. This is ordinary change management, and it is much easier to do deliberately now than under deadline pressure later.

Scope: which trials ICH M11 covers

What it covers: M11 is written for interventional clinical trials of medicinal products, across all phases and therapeutic areas. Why it matters: it is broad, so most sponsors are in scope. What to do: assume M11 applies to your interventional drug trials unless Health Canada says otherwise.

According to ICH, the harmonised protocol applies to interventional clinical trials of medicinal products across all phases and therapeutic areas, and covers pharmaceuticals, biologics, vaccines, drug-device combination products and cell or gene therapy products. Health Canada's notice does not add its own narrower scope statement, so the ICH scope is the working assumption. Non-interventional and observational studies sit outside the interventional scope that M11 is written for. If your programme spans several product types, M11 gives you one protocol structure for all of them, which is one of its main attractions for sponsors with mixed pipelines. International alignment is the wider context here, the same force behind the EU pharmaceutical package and other harmonisation efforts.

Looking ahead to Phase 2: protocols as structured data

What it is: the future state in which a protocol is submitted as structured electronic data rather than a fixed document. Why it matters: it changes the tools and skills your team needs, not just the template. What to do: understand the direction and build capability gradually rather than all at once.

Phase 2 is where the Technical Specification earns its place. Instead of a PDF that a reviewer reads page by page, a structured protocol carries its content as tagged data elements, each with a defined meaning, so that systems can read, compare and reuse the information. For a regulator, that means faster and more consistent review, easier cross-study comparison, and the ability to connect protocol content to downstream systems. For a sponsor, it means the protocol stops being a document that is retyped into other systems and becomes a single source of truth that feeds them.

Getting there is not only a technology purchase. It depends on writing protocols cleanly against the M11 template, so that each piece of content already sits under the heading that maps to a data element. A sponsor that adopts the template well in Phase 1 does most of the hard work for Phase 2 in advance. A sponsor that treats Phase 1 as a cosmetic relabel will find that its content does not map neatly when structured submission arrives. This is why Health Canada is engaging technology vendors and contract research organisations now, and why sponsors should bring those partners into the conversation early rather than waiting for a Phase 2 date.

How to prepare now: an ICH M11 readiness checklist

Use this checklist to move from awareness to readiness:

Download the ICH M11 guideline, protocol template and technical specification from ICH, and the Health Canada notice.
Map your current protocol template to the M11 standardised table of contents and universal headings.
Rebuild your authoring template around the M11 structure, with instructions for where each type of content belongs.
Update your protocol standard operating procedures and writing guidance to reference M11.
Brief medical writing, regulatory and quality teams on the new layout so reviews do not fight the template.
Pilot the M11 template on your next protocol and capture lessons before wider rollout.
Confirm the current expectation with Health Canada through the ICH coordinator channel for any active submission.
Track Health Canada communications for Phase 2 technical specifications, guidance and timelines.
Engage your technology vendors and contract research organisations early on structured-data readiness for Phase 2.

Common mistakes to avoid

The first mistake is treating M11 as a far-off technology project and doing nothing now, when Phase 1 is a document change you can make today. The second is adopting the template superficially, keeping your old section order under new headings, which defeats the harmonisation and creates confusion when Phase 2 arrives. The third is assuming a mandatory date exists, or assuming none will ever come, instead of confirming with Health Canada for the submission in front of you. The fourth is ignoring the knock-on documents, so the protocol follows M11 but the statistical analysis plan and consent materials do not line up. The fifth is leaving vendors and contract research organisations out of the conversation until structured submission is announced, which turns Phase 2 into a scramble. Each of these is avoidable with a deliberate, phased adoption plan.

Frequently asked questions

What is ICH M11 CeSHarP in simple terms?

It is an ICH guideline that gives clinical trial protocols a common structure and standardised content, delivered as a guideline, a protocol template and a technical specification. The aim is consistent protocols that are easier to review and, in time, exchangeable as structured data.

Has Health Canada adopted ICH M11?

Yes. Health Canada has published a notice beginning the phased implementation of ICH M11. Phase 1, document-based submission in PDF or Word, is in effect now, and Phase 2, structured electronic submission, will follow once Health Canada publishes the technical specifications, guidance and timelines.

Do I have to use the M11 template for my next Canadian protocol?

Health Canada's notice does not publish a mandatory date and frames Phase 1 as something sponsors may now begin. There is no published requirement to use it for every submission yet, but adoption is encouraged and is the direction of travel. Confirm the current expectation with Health Canada for any active application.

What formats does each phase use?

Phase 1 uses familiar document formats, PDF or DOCX. Phase 2 will use structured electronic formats such as JSON or XML. Health Canada has not set a date for Phase 2.

Which trials does ICH M11 apply to?

ICH writes M11 for interventional clinical trials of medicinal products across all phases and therapeutic areas, covering pharmaceuticals, biologics, vaccines, drug-device combinations and cell or gene therapy products. Non-interventional studies are outside that interventional scope.

How is M11 different from ICH E6 Good Clinical Practice?

ICH E6 sets the principles of Good Clinical Practice for how trials are conducted. ICH M11 is narrower and specific: it standardises the structure and content of the protocol document itself. The two work together, with M11 shaping the document that an E6-compliant trial runs on.

When should we start preparing?

Now. Phase 1 is a document change you can make immediately, and adopting the template early makes the Phase 2 move to structured data far simpler. Early adoption also spreads the change management over time rather than forcing it under a future deadline.

How MFLRC can help

MFLRC helps clinical trial sponsors, biotechs and contract research organisations adopt ICH M11 in a way that is practical and inspection-ready. We map your current protocol template to the M11 structure, rebuild your authoring template and writing guidance, and update the standard operating procedures that govern protocol development and review. We brief your medical writing, regulatory and quality teams, pilot the template on a live protocol, and build a readiness plan for Phase 2 structured submission. Alongside M11, our regulatory affairs team supports clinical trial applications, amendments and lifecycle submissions to Health Canada, and our quality team keeps your trial master file and quality system aligned with Good Clinical Practice.

If you want to standardise on M11 before structured submission becomes the norm, or you need a second opinion on how to interpret the phased notice for a live application, we can help.

Book an ICH M11 readiness review

Conclusion

ICH M11 is a quiet but meaningful change to how clinical trial protocols are written and, eventually, exchanged. Health Canada has opened Phase 1, so the document change is available to sponsors today, while Phase 2 and structured submission remain a known future with no fixed date. The sponsors who benefit most will not wait for a mandatory deadline. They will adopt the M11 template now, rebuild their authoring process around it, bring their vendors and contract research organisations into the plan, and confirm expectations with Health Canada for live submissions. Harmonisation rewards the organisations that move early, and M11 is a clear invitation to do exactly that.